Mayo Clinic researchers and collaborators have identified a previously unrecognized way lung tumors weaken the immune system, helping explain why many patients do not respond to immunotherapy and ...
Resistant cells demonstrated global decreases in DNA accessibility with localized opening at resistance-driving loci, indicating non-mutational epigenetic reprogramming rather than canonical oncogenic ...
Sora Ely, MD, emphasized that national lung cancer screening rates remain below 10%, underscoring the urgent need for greater ...
Early immunochemotherapy improves survival and CD8 T cell responses in advanced non small cell lung cancer without added toxicity.
Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 3:15 PM ESTCompany ParticipantsJean-Charles Soria - Senior Vice ...
The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.
1don MSN
My teen son picked up a dirty habit to look cool for his friends. He got a deadly lung condition
A Kentucky mom is issuing an urgent warning to other parents after her 17-year-old son's left lung collapsed twice from a ...
The firm said a Phase III trial, comparing adjuvant Retevmo against placebo, met its primary endpoint of event-free survival.
Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by ...
Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...
In this study, researchers reported on 10-year follow-up of a phase 3 trial comparing surgery to chemoradiation boost in resectable, advanced NSCLC.
Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results